Chemotherapy of the filariases

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 439-443

  Grove, David I ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTINEMATODAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN;

BRUGIA; EDEMA; FILARIASIS; LYMPHADENITIS; LYMPHADENOPATHY; ONCHOCERCIASIS; PAIN; SHORT SURVEY; WUCHERERIA BANCROFTI;

EID: 0030445308     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00017     Document Type: Short Survey

References (31)

1. McCarthy JS, Guinea A, Weil GJ, Ottesen EA: Clearance of circulating filarial antigen as a measure of macrofilaricidal activity of diethylcarbamazine in Wuchereria bancrofti infection. J Infect Dis 1995, 172:521-526.
2. Dreyer G, Amaral F, Norōes J, Medeiros Z, Addiss D: A new tool to assess the adulticidal efficacy in vivo of antifilarial drugs for bancroftian filariasis. Trans R Soc Trop Med Hyg 1995, 89:225-226.
3. Figueredo-Silva J, Jungmann P, Norōes J, Piessens W, Coutinho A, Brito C, Rocha A, Dreyer G: Histological evidence for adulticidal effect of low doses of diethylcarbamazine in bancroftian filariasis. Trans R Soc Trop Med Hyg 1996, 90:192-194. An informative description of histopathological changes in lymphatic nodules appearing after treatment with diethylcarbamazine in patients with bancroftian filariasis.
4. Dreyer G, Norōes J, Amaral F, Nen A, Medeiros Z, Coutinho A, Addiss D: Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariais. Trans R Soc Trop Med Hyg 1995, 89:441-443. An innovative approach using ultrasonography to demonstrate characteristic movements of living adult W. bancrofti after ivermectin treatment. These findings were then supplemented with histological studies.
5. Freedman DO, Bui T, de Almeida Filho PJ, Braga C, Maia E, Silva MC, Maciel A, Furtado AF: Lymphoscintigraphic assessment of the effect of diethylcarbamazine treatment on lymphatic damage in human bancroftian filariasis. Am J Trop Med Hyg 1995, 52:258-261.
6. Fan PC, Peng HW, Chenn CC: Follow-up investigations on clinical manifestation after filariasis eradication by diethylcarbamazine medicated common salt on Kinmen (Quemoy) Islands, Republic of China J Trop Med Hyg 1995, 98:461-464.
7. Andrade LD, Medeiros Z, Pires ML, Pimentel A, Rocha A, Figueredo-Silva J, Coutinho A, Dreyer G: Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Trans R Soc Trop Med Hyg 1995, 89:319-321. Patients with W. bancrofti microfilaraemia in Brazil were given diethylcarbamazine 6 mg/kg a day for 12 days, 6 mg/kg once, or 2 mg/kg three times on 1 day. After 12 months, there was little difference between the three groups with 40-42% of patients being amicrofilaraemic and similar suppressions in overall mean microfilaraemia densities were shown.
8. Hakim SL, Vythilingam I, Marzukhi MI, Mak JW: Single-dose diethylcarbamazine in the control of periodic brugian filariasis in peninsular Malaysia. Trans R Soc Trop Med Hyg 1995, 89:696-689.
9. Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P: Selective diethylcarbamazine chemotherapy for control of bancroftian filariasis in two communities of Tanzania: compared efficacy of a standard dose treatment and two semi-annual single dose treatments. Am J Trop Med Hyg 1995, 53:267-272.
10. Meyrowitsch DW, Simonsen PE, Makunde WH: Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis: comparative efficacy of standard treatment and two semi-annual single dose treatments Trans R Soc Trop Med Hyg 1996, 90:69-73.
11. Meyrowitsch DW, Simonsen PE, Makunde WH: Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of low monthly dose and medicated salt. Trans R Soc Trop Med Hyg 1996, 90:74-79.
12. Reddy GS, Venkateswaralu N: Mass administration of diethylcarb-mazine-medicated salt for filariasis controlling the endemic population of Karaikal, South India: implementation and impact assessment. Bull WHO 1996, 74:85-90. Salt containing diethylcarbamazine in a concentration of 0.1-0.2 mg/100 mg was given to the entire population of Karaikal (119978) for a 4-year period from 1982, with a per capita consumption of 13.3 g of diethylcarbamazine during that period. The prevalence of microfilaraemia fell from 4.5% in 1982 to 0.14% in 1985 but rose again to 0.4% in 1993. Techniques useful for ensuring the administration of diethylcarbamazine in salt to a population are very well described.
13. Bryan JH, Dagoro H, Southgate BA: Filarial vector studies in a diethylcarbamazine-treated and in untreated villages in Papua New Guinea. J Trop Med Hyg 1995, 98:445-451.
14. Sartono S, Kruize YCM, Kurniawan A, van der Meide PH, Partono F, Maizels RM, Yazdanbakhsh M: Elevated cellular immune responses and interferon-γ release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. J Infect Dis 1995, 171:1683-1687.
15. Atmadja AK, Atkinson R, Sartono E, Partono F, Yazdanbakhsh M, Maizels RM: Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine therapy. J Infect Dis 1995, 172:1567-1572.
16. Chodakewitz J: Ivermectin and lymphatic filariasis: a clinical update. Parasitol Today 1995, 11:233-235. A valuable review of a number of studies examining the efficacy of ivermectin in lymphatic filariasis.
17. Moulia-Pelat JP, Nguyen LN, Hascoët H, Luquiaud P, Nicolas L: Advantages of an annual single dose of ivermectin 400 μg/kg plus diethylcarbamazine for community treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1995, 89:682-685.
18. Boussinesq M, Chippaux JP, Ernould JC, Quillevere D, Prod'hon J: Effect of repeated treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. Am J Trop Med Hyg 1995, 53:63-67.
19. Whitworth JAG, Downham MD, Lahai G, Maude GH: A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of ivermectin. Trop Med Int Hlth 1996, 1:52-58.
20. Rodriguez-Perez MA, Rodriguez MH, Margeli-Perez HM, Rivas-Alcala AR: Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico. Am J Trop Med Hyg 1995, 52:429-434.
21. Chavasse DC, Whitworth JA, Lemoh PA, Bennett S, Davies JB: Low-level ivermectin coverage and the transmission of onchocerciasis. Trans R Soc Trop Med Hyg 1995, 89:534-537.
22. Baraka OZ, Mahmoud BM, Ali MMM, Ali MH, El Sheik EA, Homeida MMA, Mackenzie CD, Williams JF: Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan. Trans R Soc Trop Med Hyg 1995, 89:312-315.
23. Baraka OZ, Khier MM, Ahmed KM, Ali MMM, El Mardi AE, Mahmoud BM, Ali MH, Homeida MMA, Williams JF: Community based distribution of ivermectin in eastern Sudan: acceptability and post-treatment reactions. Trans R Soc Trop Med Hyg 1995, 89:316-318.
24. Hewlett BS, Kollo B, Cline BL: Ivermectin distribution and the cultural context of forest onchocerciasis in South Province, Cameroon. Am J Trop Med Hyg 1996, 54:517-522.
25. Gardon J, Macé JM, Cadot E, Ogil C, Godin C, Boussinesq M: Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment. Trans R Soc Trop Med Hyg 1996, 90:218-222.
26. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, Bonneux L, Habbema JDF: Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the onchocerciasis control programme in West Africa. J Infect Dis 1995, 172:204-210.
27. Awadzi K, Opoku NO, Addy ET, Quartey BT: The chemotherapy of onchocerciasis XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 1995, 46:131-137.
28. Anosike JC, Abanobi OC: Reversal of amenorrhoea after Mectizan treatment. Trop Geogr Med 1995, 47:222-224.
29. Fischer P, Kipp W, Kabwa P, Buttner D: Onchocerciasis and human immunodeficiency virus in western Uganda: prevalence and treatment with ivermectin. Am J Trop Med Hyg 1995, 53:171-178. HIV-positive patients with onchocerciasis had a mean density of 11.9 microfilariae/mg skin compared with 17.7 microfilariae/mg in HIV-negative patients. Ivermectin treatment resulted in 65% and 49% reductions in skin microfilarial densities in the two groups, respectively.
30. Akuffo H, Maasho K, Lavebratt C, Engstrom K, Britton S: Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin. Clin Exp Immunol 1996, 103:244-252.
31. Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, Chippaux JP: Effets secondaires du traitement de la loase hypermicrofilaremique par l'ivermectine. Bull Soc Pathol Exor 1995, 88:105-112.